HER2+ Breast Cancer

Keerthi Gogineni, MD, MSHP, discusses several trials in the breast cancer field, specifically looking at de-escalation therapies.

Health Canada has approved neratinib (Nerlynx) for the extended adjuvant treatment of patients with early-stage, hormone receptor–positive, HER2-overexpressed/amplified breast cancer within 1 year after completing trastuzumab (Herceptin)-based adjuvant therapy.

Michel Velez, MD, medical oncologist at Holy Cross Hospital, discusses the management of neratinib (Nerlynx)-associated diarrhea in patients with early-stage HER2-positive breast cancer.

An application has been submitted to the FDA for neratinib for use in combination with capecitabine for the third-line treatment of patients with HER2-positive metastatic breast cancer.

Yee Chung Cheng, MD, discusses the importance of integrating neoadjuvant and adjuvant trial data into practice in order to optimize outcomes for patients with early-stage HER2-positive breast cancer.

Ross Mudgway, discusses the importance of considering surgery for patients with stage IV HER2-positive breast cancer and addresses disparities in healthcare among different social groups.

Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses unmet needs beyond second-line treatment in HER2+ breast cancer.

Melody A. Cobleigh, MD, a professor of medical oncology at Rush University Medical Center, discusses the focus of future research in HER2-positive breast cancer.

Yee Chung Cheng, MD, associate professor of medicine, Medical College of Wisconsin, discusses the role of T-DM1 in patients with HER2-positive breast cancer.

Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the phase III SOPHIA trial of margetuximab plus chemotherapy versus trastuzumab (Herceptin) plus capecitabine in patients with HER2-positive metastatic breast cancer after prior anti–HER2-targeted therapies.

Joanne Mortimer, MD, associate director for Education and Training, Comprehensive Cancer Center, Baum Family Professor in Women’s Cancers, vice chair and professor, Department of Medical Oncology and Therapeutics Research, director, Women’s Cancer Programs, and breast cancer oncologist, City of Hope, discusses brain metastases in women with HER2-positive breast cancer.

Lauren Nye, MD, assistant professor, University of Kansas Medical Center, discusses the concern of neratinib-associated diarrhea in patients with HER2-positive breast cancer.

Joanne Mortimer, MD, discusses key facets of treatment for patients with early and metastatic HER2-positive breast cancer.

The antibody-drug conjugate [fam-] trastuzumab deruxtecan (DS-8201) demonstrated encouraging responses in patients with unresectable and/or metastatic HER2-positive breast cancer that has been previously treated with ado-trastuzumab emtansine, according to topline findings from the phase II DESTINY-BreastO1 study.

The FDA has approved ado-trastuzumab emtansine (T-DM1; Kadcyla) for use as an adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant trastuzumab and chemotherapy.

Joanne Mortimer, MD, associate director for Education and Training, Comprehensive Cancer Center, Baum Family Professor in Women’s Cancers, vice chair and professor, Department of Medical Oncology & Therapeutics Research, director, Women’s Cancer Programs, City of Hope, discusses adjuvant therapy in early-stage HER2-positive breast cancer.

A new VENTANA HER2 dual in situ hybridization companion diagnostic assay has launched to identify HER2 amplification for patients with breast cancer and gastric cancer who could be eligible to receive trastuzumab.

Cindy Osborne, MD, highlights the many advances that have been made in the treatment paradigms of locally advanced and metastatic HER2-positive breast cancer.

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses overcoming resistance to HER2-targeted therapy in breast cancer.

Mark D. Pegram, MD, highlights data from pivotal studies that have helped to shape the current landscape of HER2-positive breast cancer and sheds light on emerging agents that are showing promise in the pipeline.

Melody A. Cobleigh, MD, professor of medical oncology at Rush University Medical Center, discusses antibody–drug conjugates (ADCs) under development in HER2-positive breast cancer.

An accelerated filing of a biologics license application is planned for [fam-] trastuzumab deruxtecan (DS-8201) as a treatment for patients with HER2-positive metastatic breast cancer previously treated with ado-trastuzumab emtansine.

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses toxicity associated with neratinib in the treatment of patients with HER2-positive breast cancer.

Melody A. Cobleigh, MD, sheds light on novel treatment approaches for patients with HER2-positive breast cancer that are under investigation as well as strategies that have already been incorporated into practice.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses promising novel agents in the treatment of patients with HER2-positive metastatic breast cancer.